By Donna Loyle, communications specialist, LIMR
Researchers are conducting a randomized clinical trial to determine if the experimental drug cediranib maleate and the FDA-approved Lynparza™ (olaparib) may stop the growth of ovarian, fallopian tube and primary peritoneal tumor cells by blocking enzymes needed for cell growth. They are comparing the drug regimen to non-platinum standard chemotherapy.
This trial is for previously treated patients with recurrence of the above-noted cancers.
Eligible patients are those deemed platinum-resistant or -refractory. Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must either serous or endometrioid cancer based on local histopathological findings. Both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers.
Patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided the patient has a known deleterious germline BRCA1 or BRCA2 mutation. Other inclusion/exclusion criteria apply. Please see the website for additional information.
Study participants are grouped into three treatment arms:
- standard non-platinum chemotherapy
- cediranib maleate and olaparib
- only cediranib maleate
Patients undergo follow-up care for up to five years.
Trial NRG GY005 is approved for Lankenau Medical Center and Paoli Hospital. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more information, visit https://www.mainlinehealth.org/research/clinical-trials/nrg-gy005